Apricus Biosciences to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Tuesday, August 12, 2014

Follow this company

Companies Mentioned

08/11/2014 [ACCESSWIRE]

SAN DIEGO, CA / ACCESSWIRE / August 11, 2014 / Apricus Biosciences, Inc. (NASDAQ: APRI) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Tuesday, August 12, 2014 at 8:00 AM Eastern Time.

To participate in this event, dial 877-407-9210 domestically, or 201-689-8049 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=173060 as well as via the Apricus Biosciences, Inc. website (www.apricusbio.com). 

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com/ClientPage.asp?ID=173060 or www.apricusbio.com.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID #13588208. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on November 12, 2014. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company focused on the development and commercialization of novel therapeutics for men's and women's health. The Company's lead product, Vitaros(TM), for the treatment of erectile dysfunction, is approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros(TM) room temperature device is under development and is expected to enhance the product's commercial value. RayVa(TM), the Company's product candidate for the treatment of Raynaud's phenomenon, recently received FDA clearance to begin clinical studies. The Company intends to begin a Phase 2a trial with RayVa in the second half of 2014. Femprox(TM), the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox.
For further information on Apricus, visit www.apricusbio.com


SOURCE: Apricus Biosciences, Inc.


Leave a comment...

Your Name